Beneficial effects of ulinastatin on gut barrier function in sepsis

Indian Journal of Medical Research

Volumn 138, Issue DEC, 2013, Pages 904-911

  Jiang, Longyuan ^a   Yang, Lianhong ^a   Zhang, Meng ^a   Fang, Xiangshao ^a   Huang, Zitong ^a   Yang, Zhengfei ^a   Zhou, Tianen ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Gut barrier; IL 6,Sepsis; TNF ; Ulinastatin

Indexed keywords

GLYCOPROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ANIMAL; APOPTOSIS; BLOOD; DRUG EFFECTS; GASTROINTESTINAL TRACT; MALE; MICROBIOLOGY; PATHOLOGY; SEPSIS; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; GASTROINTESTINAL TRACT; GLYCOPROTEINS; INTERLEUKIN-6; MALE; RATS, SPRAGUE-DAWLEY; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893300214     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Martin GS. Sepsis: the future is bright. Crit Care Med 2006; 34: 2484-5.
2. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
3. Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 2006; 103: 1074-81.
4. Lazar HL, Bao Y, Tanzillo L, O'Gara P, Reardon D, Price D, et al. Aprotinin decreases ischemic damage during coronary revascularization. J Card Surg 2005; 20: 519-23.
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
6. Kanwar S, Windsor AC, Welsh F, Barclay GR, Guillou PJ, Reynolds JV. Lack of correlation between failure of gut barrier function and septic complications after major upper gastrointestinal surgery. Ann Surg 2000; 231: 88-95.
7. Suliburk J, Helmer K, Moore F, Mercer D. The gut in systemic inflammatory response syndrome and sepsis. Enzyme systems fighting multiple organ failure. Eur Surg Res 2008; 40: 184-9.
8. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
9. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286: 113-7.
10. Flaujac C, Pouard P, Boutouyrie P, Emmerich J, Bachelot-Loza C, Lasne D. Platelet dysfunction after normothermic cardiopulmonary bypass in children: effect of high-dose aprotinin. Thromb Haemost 2007; 98: 385-91.
11. Ren B, Wu H, Zhu J, Li D, Shen Y, Ying R, et al. Ulinastatin attenuates lung ischemia-reperfusion injury in rats by inhibiting tumor necrosis factor alpha. Transplant Proc 2006; 38: 2777-9.
12. Royston D, Levy JH, Fitch J, Dietrich W, Body SC, Murkin JM, et al. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg 2006; 103: 1082-8.
13. Eser O, Kalkan E, Cosar M, Buyukbas S, Avunduk MC, Aslan A, et al. The effect of aprotinin on brain ischemic-reperfusion injury after hemorrhagic shock in rats: an experimental study. J Trauma 2007; 63: 373-8.
14. Li Y, Chen H, Li X, Zhou W, He M, Chiriva-Internati M, et al. A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1. J Intensive Care Med 2009; 24: 47-53.
15. Condon MR, Viera A, D'Alessio M, Diamond G. Induction of a rat enteric defensin gene by hemorrhagic shock. Infect Immun 1999; 67: 4787-93.
16. Parker SJ, Watkins PE. Experimental models of gram-negative sepsis. Br J Surg 2001; 88: 22-30.
17. Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 2009; 119: 2868-78.
18. Huang CY, Hsiao JK, Lu YZ, Lee TC, Yu LC. Anti-apoptotic PI3K/Akt signaling by sodium/glucose transporter 1 reduces epithelial barrier damage and bacterial translocation in intestinal ischemia. Lab Invest 2011; 91: 294-309.
19. Hyoh Y, Ishizaka S, Horii T, Fujiwara A, Tegoshi T, Amada M, Arizomo N. Activation of caspases in intestinal villus epithelial cells of normal and nematode infected rats. Gut 2002; 50: 71-7.
20. Mastroianmi JR, Ouellette AJ. Alpha-defensinsin enteric innate immunity: functional Paneth cell alpha-defensins in mouse colonic lumen. J Biol Chem 2009; 284: 27848-56.
21. Ponnala L. Detecting slow-translating regions in E. coli. Int J Bioinform Res Appl 2010; 6: 521-30.
22. Li KY, Jiang LY, Zhang M, Zhong M, Xie WZ. Effects of ulinastatin on gut mucosal apoptosis and bacterial translocation in rats with sepsis. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28: 1244-6.
23. Cao YZ, Tu YY, Chen X, Wang BL, Zhong YX, Liu MH. Protective effect of Ulinastatin against murine models of sepsis: Inhibition of TNF-alpha and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol 2012; 64: 543-7.
24. Kim SJ, Yoo KY, Jeong CW, Kim WM, Lee HK, Bae HB, et al. Urinary trypsin inhibitors afford cardioprotective effects through activation of PI3K-Akt and ERK signal transduction and inhibition of p38 MAPK and JNK. Cardiology 2009; 114: 264-70.
25. Li XK, Suzuki H, Kimura T, Kawabe A, Uno T, Harada Y. Ulinastatin, a protease inhibitor, attenuates intestinal ischemia/reperfusion injury. Transplant Proc 1994; 26: 2423-5.
26. Yang R, Han X, Uchiyama T, Watkins SK, Yaguchi A, Delude RL, et al. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol 2003; 285: G621-9.
27. Wang Q, Fang CH, Hasselgren PO. Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1013-23.
28. Spies M, Chappell VL, Dasu MR, Herndon DN, Thompson JC, Wolf SE. Role of TNF-alpha in gut mucosal changes after severe burn. Am J Physiol Gastrointest Liver Physiol 2002; 283: G703-8.
29. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-62.
30. Inoue K, Takano H, Shimada A, Yanagisawa R, Sakurai M, Yoshino S, et al. Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol 2005; 67: 673-80.
31. Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept 2001; 101: 157-61.
32. Qiu X, Ji S, Wang J, Li H, Xia T, Pan B, et al. The therapeutic efficacy of Ulinastatin for rats with smoking inhalation injury. Int Immunopharmacol 2012; 14: 289-95.
33. Chavan SS, Huerta PT, Robbiati S, Valdes-Ferrer SI, Ochani M, Dancho M, et al. HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med 2012; 18: 930-7.